Intocell Inc
287840
Company Profile
Business description
Intocell Inc possesses independent linker platform technology in the ADC (Antibody-Drug Conjugate) field, which is in the spotlight in the anticancer drug market. The company is researching linker technology that conjugates with drugs and drugs for ADC. The business model of the company is to continuously secure sales through platform technology export that allows linker platform technology to be applied to partner companies' antibodies, and technology export of ADC pipelines.
Contact
101 Sinildong-ro
Daedeok-gu
Daejeon
KORT: +82 427160083
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
43
Stocks News & Analysis
stocks
This ASX miner is the cheapest in our iron ore coverage
High debt levels and low commodity prices were a concern, but agreed sell-downs and a ramp-up of key operations should help.
stocks
Apple names new CEO as Tim Cook steps aside after 15 years
John Ternus, Apple’s hardware chief, will take up the role in September.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,074.40 | 50.80 | -0.56% |
| CAC 40 | 8,203.36 | 32.35 | -0.39% |
| DAX 40 | 24,220.56 | 50.31 | -0.21% |
| Dow JONES (US) | 49,527.09 | 377.71 | 0.77% |
| FTSE 100 | 10,486.57 | 11.52 | -0.11% |
| HKSE | 26,163.24 | 324.24 | -1.22% |
| NASDAQ | 24,426.86 | 166.89 | 0.69% |
| Nikkei 225 | 59,585.86 | 236.69 | 0.40% |
| NZX 50 Index | 12,945.60 | 13.27 | 0.10% |
| S&P 500 | 7,109.69 | 45.68 | 0.65% |
| S&P/ASX 200 | 8,843.60 | 53.20 | -0.60% |
| SSE Composite Index | 4,106.26 | 21.18 | 0.52% |